Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs

MÅLØV, Denmark (Reuters) – Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as prices for its established diabetes drugs come under pressure, particularly in the United States.

Source: Reuters Health

Leave a Reply

Your email address will not be published. Required fields are marked *